Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-18

AUTHORS

Venkatraman Radhakrishnan, Anand Raja, Manikandan Dhanushkodi, T. S. Ganesan, G. Selvaluxmy, T. G. Sagar

ABSTRACT

OBJECTIVES: Management of neuroblastoma, especially high-risk (HR) disease is difficult in a resource-limited setting. There is a paucity of literature on outcomes of patients treated in India. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at authors' centre. METHODS: The study was a retrospective analysis of newly diagnosed patients with neuroblastoma treated at authors' centre between 2000 to 2017. The International Neuroblastoma Staging System and risk grouping were used to classify patients as low-risk (LR), intermediate-risk (IR) and high-risk (HR). Treatment was individualised and risk-adapted. Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS). RESULTS: The study included 85 patients with a median age of 4 y and 67% were males. Malnutrition was observed in 55% of patients. Adrenal gland was the most common site in 75% patients followed by mediastinum in 12%. LR was observed in 7/85 (8%) patients, IR 20/85 (24%) and HR in 58/85 (68%) patients. The CCG-3891 protocol was used to treat 80% of the patients. Autologous stem cell transplantation (ASCT) was performed in 32% of HR patients. The median follow-up was 16.6 mo. The median EFS and OS for all patients were 19.2 mo and 26.9 mo respectively and the 3 y EFS and OS was 36% and 47% respectively. The 3y EFS for LR, IR and HR patients was 100%, 54%, and 18.9% respectively (P < 0.001) and for OS was 100%, 77%, and 34% respectively (P = 0.002). On multivariate analysis, a hemoglobin less than 10 g% predicted inferior EFS (P = 0.002) and OS (p = 0.005) for all patients. For patients with high-risk disease, on multivariate analysis, hemoglobin (P = 0.002) and 13-Cis Retinoic acid maintenance (P = 0.002) predicted EFS and only radiotherapy to the primary (P = 0.01) predicted OS. Only 4/19 (21%) are alive and in remission post ASCT. CONCLUSIONS: Majority of patients with neuroblastoma presented to authors' centre with advanced disease. Survival outcomes of patients with LR disease are excellent. However, patients with HR disease have poor outcomes despite multimodality management. Non-availability of N-MYC testing in few patients could have falsely down-staged them to IR from HR. A low hemoglobin at diagnosis is a poor predictor of outcome. More... »

PAGES

1-10

References to SciGraph publications

  • 2013-10. Outcome of Neuroblastoma in India in THE INDIAN JOURNAL OF PEDIATRICS
  • 1999-11. Intensive chemotherapy in children with stage IV neuroblastoma in THE INDIAN JOURNAL OF PEDIATRICS
  • Journal

    TITLE

    The Indian Journal of Pediatrics

    ISSUE

    N/A

    VOLUME

    N/A

    Author Affiliations

    Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12098-018-2834-6

    DOI

    http://dx.doi.org/10.1007/s12098-018-2834-6

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1112213424

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30778950


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Radhakrishnan", 
            "givenName": "Venkatraman", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Raja", 
            "givenName": "Anand", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dhanushkodi", 
            "givenName": "Manikandan", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ganesan", 
            "givenName": "T. S.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Radiotherapy, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Selvaluxmy", 
            "givenName": "G.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Institute", 
              "id": "https://www.grid.ac/institutes/grid.418600.b", 
              "name": [
                "Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sagar", 
            "givenName": "T. G.", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-14-0817", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000206075"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2008.16.6876", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012354207"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02723857", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012833849", 
              "https://doi.org/10.1007/bf02723857"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02723857", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012833849", 
              "https://doi.org/10.1007/bf02723857"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.jpedsurg.2014.03.017", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016066112"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2007.13.8925", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016119423"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/pbc.24671", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019380970"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa1001527", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025117237"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12098-012-0948-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025346649", 
              "https://doi.org/10.1007/s12098-012-0948-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/pbc.20219", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028702565"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s1470-2045(05)70291-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029499017"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s1470-2045(05)70291-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029499017"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa0911123", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031306714"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/pbc.25501", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042165606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2967/jnumed.108.060467", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042526688"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047684161"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1055/s-0042-103158", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1057376046"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077614270", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1148/rg.2016150099", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1079210596"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1993.11.8.1466", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082762676"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1998.16.4.1256", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083246609"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/pbc.26545", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084516606"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-02-18", 
        "datePublishedReg": "2019-02-18", 
        "description": "OBJECTIVES: Management of neuroblastoma, especially high-risk (HR) disease is difficult in a resource-limited setting. There is a paucity of literature on outcomes of patients treated in India. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at authors' centre.\nMETHODS: The study was a retrospective analysis of newly diagnosed patients with neuroblastoma treated at authors' centre between 2000 to 2017. The International Neuroblastoma Staging System and risk grouping were used to classify patients as low-risk (LR), intermediate-risk (IR) and high-risk (HR). Treatment was individualised and risk-adapted. Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS).\nRESULTS: The study included 85 patients with a median age of 4 y and 67% were males. Malnutrition was observed in 55% of patients. Adrenal gland was the most common site in 75% patients followed by mediastinum in 12%. LR was observed in 7/85 (8%) patients, IR 20/85 (24%) and HR in 58/85 (68%) patients. The CCG-3891 protocol was used to treat 80% of the patients. Autologous stem cell transplantation (ASCT) was performed in 32% of HR patients. The median follow-up was 16.6 mo. The median EFS and OS for all patients were 19.2 mo and 26.9 mo respectively and the 3 y EFS and OS was 36% and 47% respectively. The 3y EFS for LR, IR and HR patients was 100%, 54%, and 18.9% respectively (P\u2009<\u20090.001) and for OS was 100%, 77%, and 34% respectively (P\u2009=\u20090.002). On multivariate analysis, a hemoglobin less than 10\u00a0g% predicted inferior EFS (P\u2009=\u20090.002) and OS (p\u2009=\u20090.005) for all patients. For patients with high-risk disease, on multivariate analysis, hemoglobin (P\u2009=\u20090.002) and 13-Cis Retinoic acid maintenance (P\u2009=\u20090.002) predicted EFS and only radiotherapy to the primary (P\u2009=\u20090.01) predicted OS. Only 4/19 (21%) are alive and in remission post ASCT.\nCONCLUSIONS: Majority of patients with neuroblastoma presented to authors' centre with advanced disease. Survival outcomes of patients with LR disease are excellent. However, patients with HR disease have poor outcomes despite multimodality management. Non-availability of N-MYC testing in few patients could have falsely down-staged them to IR from HR. A low hemoglobin at diagnosis is a poor predictor of outcome.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s12098-018-2834-6", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1019636", 
            "issn": [
              "0019-5456", 
              "0973-7693"
            ], 
            "name": "The Indian Journal of Pediatrics", 
            "type": "Periodical"
          }
        ], 
        "name": "Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India", 
        "pagination": "1-10", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "22e464881d95142652149a345304b5118feffa65aef84d6a4401e65dee2c2b98"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30778950"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0417442"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12098-018-2834-6"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1112213424"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12098-018-2834-6", 
          "https://app.dimensions.ai/details/publication/pub.1112213424"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T09:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000338_0000000338/records_47997_00000002.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1007%2Fs12098-018-2834-6"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12098-018-2834-6'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12098-018-2834-6'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12098-018-2834-6'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12098-018-2834-6'


     

    This table displays all metadata directly associated to this object as RDF triples.

    155 TRIPLES      21 PREDICATES      46 URIs      18 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12098-018-2834-6 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 schema:author Nff02879918904e47ae4989bf6d54505a
    4 schema:citation sg:pub.10.1007/bf02723857
    5 sg:pub.10.1007/s12098-012-0948-9
    6 https://app.dimensions.ai/details/publication/pub.1077614270
    7 https://doi.org/10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7
    8 https://doi.org/10.1002/pbc.20219
    9 https://doi.org/10.1002/pbc.24671
    10 https://doi.org/10.1002/pbc.25501
    11 https://doi.org/10.1002/pbc.26545
    12 https://doi.org/10.1016/j.jpedsurg.2014.03.017
    13 https://doi.org/10.1016/s1470-2045(05)70291-6
    14 https://doi.org/10.1055/s-0042-103158
    15 https://doi.org/10.1056/nejmoa0911123
    16 https://doi.org/10.1056/nejmoa1001527
    17 https://doi.org/10.1148/rg.2016150099
    18 https://doi.org/10.1158/1078-0432.ccr-14-0817
    19 https://doi.org/10.1200/jco.1993.11.8.1466
    20 https://doi.org/10.1200/jco.1998.16.4.1256
    21 https://doi.org/10.1200/jco.2007.13.8925
    22 https://doi.org/10.1200/jco.2008.16.6876
    23 https://doi.org/10.2967/jnumed.108.060467
    24 schema:datePublished 2019-02-18
    25 schema:datePublishedReg 2019-02-18
    26 schema:description OBJECTIVES: Management of neuroblastoma, especially high-risk (HR) disease is difficult in a resource-limited setting. There is a paucity of literature on outcomes of patients treated in India. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at authors' centre. METHODS: The study was a retrospective analysis of newly diagnosed patients with neuroblastoma treated at authors' centre between 2000 to 2017. The International Neuroblastoma Staging System and risk grouping were used to classify patients as low-risk (LR), intermediate-risk (IR) and high-risk (HR). Treatment was individualised and risk-adapted. Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS). RESULTS: The study included 85 patients with a median age of 4 y and 67% were males. Malnutrition was observed in 55% of patients. Adrenal gland was the most common site in 75% patients followed by mediastinum in 12%. LR was observed in 7/85 (8%) patients, IR 20/85 (24%) and HR in 58/85 (68%) patients. The CCG-3891 protocol was used to treat 80% of the patients. Autologous stem cell transplantation (ASCT) was performed in 32% of HR patients. The median follow-up was 16.6 mo. The median EFS and OS for all patients were 19.2 mo and 26.9 mo respectively and the 3 y EFS and OS was 36% and 47% respectively. The 3y EFS for LR, IR and HR patients was 100%, 54%, and 18.9% respectively (P < 0.001) and for OS was 100%, 77%, and 34% respectively (P = 0.002). On multivariate analysis, a hemoglobin less than 10 g% predicted inferior EFS (P = 0.002) and OS (p = 0.005) for all patients. For patients with high-risk disease, on multivariate analysis, hemoglobin (P = 0.002) and 13-Cis Retinoic acid maintenance (P = 0.002) predicted EFS and only radiotherapy to the primary (P = 0.01) predicted OS. Only 4/19 (21%) are alive and in remission post ASCT. CONCLUSIONS: Majority of patients with neuroblastoma presented to authors' centre with advanced disease. Survival outcomes of patients with LR disease are excellent. However, patients with HR disease have poor outcomes despite multimodality management. Non-availability of N-MYC testing in few patients could have falsely down-staged them to IR from HR. A low hemoglobin at diagnosis is a poor predictor of outcome.
    27 schema:genre research_article
    28 schema:inLanguage en
    29 schema:isAccessibleForFree false
    30 schema:isPartOf sg:journal.1019636
    31 schema:name Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India
    32 schema:pagination 1-10
    33 schema:productId N21499f549f2e4b84b1deec2e276114e0
    34 N2f4a43e3a0f1494c9c30a4509c366a90
    35 Nb9e3d42e82524ea3989c076106ba51dc
    36 Nbeee8dea619d4b83811c8ce28894adba
    37 Nbfe9d2adff62408abf48c9012ad1d746
    38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112213424
    39 https://doi.org/10.1007/s12098-018-2834-6
    40 schema:sdDatePublished 2019-04-11T09:14
    41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    42 schema:sdPublisher N999e587d98d34cf8a61c9a843d38934b
    43 schema:url https://link.springer.com/10.1007%2Fs12098-018-2834-6
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset articles
    46 rdf:type schema:ScholarlyArticle
    47 N0eeb8b572b0643c684232c87fbdc6380 schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    48 schema:familyName Dhanushkodi
    49 schema:givenName Manikandan
    50 rdf:type schema:Person
    51 N1fd83bdbac134fa898bc805d748fabb4 schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    52 schema:familyName Selvaluxmy
    53 schema:givenName G.
    54 rdf:type schema:Person
    55 N20122672fa334b9eb691763c563e3373 rdf:first N1fd83bdbac134fa898bc805d748fabb4
    56 rdf:rest Nd1413271033a464186ebbadd7f9f4daa
    57 N21499f549f2e4b84b1deec2e276114e0 schema:name pubmed_id
    58 schema:value 30778950
    59 rdf:type schema:PropertyValue
    60 N2f4a43e3a0f1494c9c30a4509c366a90 schema:name readcube_id
    61 schema:value 22e464881d95142652149a345304b5118feffa65aef84d6a4401e65dee2c2b98
    62 rdf:type schema:PropertyValue
    63 N3e68736ba77148998af001b02786ceb9 rdf:first N70a2c2ceaccd42249131ce6502dea2a7
    64 rdf:rest N429f9540df4c4acc885d3f660d28527d
    65 N429f9540df4c4acc885d3f660d28527d rdf:first N0eeb8b572b0643c684232c87fbdc6380
    66 rdf:rest Ned07d99fdc3148aeb890024ffd7530b9
    67 N4a418395e35b4ac79df67e7b355d9b2b schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    68 schema:familyName Radhakrishnan
    69 schema:givenName Venkatraman
    70 rdf:type schema:Person
    71 N70a2c2ceaccd42249131ce6502dea2a7 schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    72 schema:familyName Raja
    73 schema:givenName Anand
    74 rdf:type schema:Person
    75 N99683ca3b46c4d2fa06b235d4b11c854 schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    76 schema:familyName Ganesan
    77 schema:givenName T. S.
    78 rdf:type schema:Person
    79 N999e587d98d34cf8a61c9a843d38934b schema:name Springer Nature - SN SciGraph project
    80 rdf:type schema:Organization
    81 Nb9e3d42e82524ea3989c076106ba51dc schema:name dimensions_id
    82 schema:value pub.1112213424
    83 rdf:type schema:PropertyValue
    84 Nbeee8dea619d4b83811c8ce28894adba schema:name doi
    85 schema:value 10.1007/s12098-018-2834-6
    86 rdf:type schema:PropertyValue
    87 Nbfe9d2adff62408abf48c9012ad1d746 schema:name nlm_unique_id
    88 schema:value 0417442
    89 rdf:type schema:PropertyValue
    90 Nd1413271033a464186ebbadd7f9f4daa rdf:first Nfafb85a4fa09440282a243a4db2ac379
    91 rdf:rest rdf:nil
    92 Ned07d99fdc3148aeb890024ffd7530b9 rdf:first N99683ca3b46c4d2fa06b235d4b11c854
    93 rdf:rest N20122672fa334b9eb691763c563e3373
    94 Nfafb85a4fa09440282a243a4db2ac379 schema:affiliation https://www.grid.ac/institutes/grid.418600.b
    95 schema:familyName Sagar
    96 schema:givenName T. G.
    97 rdf:type schema:Person
    98 Nff02879918904e47ae4989bf6d54505a rdf:first N4a418395e35b4ac79df67e7b355d9b2b
    99 rdf:rest N3e68736ba77148998af001b02786ceb9
    100 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    101 schema:name Medical and Health Sciences
    102 rdf:type schema:DefinedTerm
    103 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    104 schema:name Clinical Sciences
    105 rdf:type schema:DefinedTerm
    106 sg:journal.1019636 schema:issn 0019-5456
    107 0973-7693
    108 schema:name The Indian Journal of Pediatrics
    109 rdf:type schema:Periodical
    110 sg:pub.10.1007/bf02723857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012833849
    111 https://doi.org/10.1007/bf02723857
    112 rdf:type schema:CreativeWork
    113 sg:pub.10.1007/s12098-012-0948-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025346649
    114 https://doi.org/10.1007/s12098-012-0948-9
    115 rdf:type schema:CreativeWork
    116 https://app.dimensions.ai/details/publication/pub.1077614270 schema:CreativeWork
    117 https://doi.org/10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047684161
    118 rdf:type schema:CreativeWork
    119 https://doi.org/10.1002/pbc.20219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028702565
    120 rdf:type schema:CreativeWork
    121 https://doi.org/10.1002/pbc.24671 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019380970
    122 rdf:type schema:CreativeWork
    123 https://doi.org/10.1002/pbc.25501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042165606
    124 rdf:type schema:CreativeWork
    125 https://doi.org/10.1002/pbc.26545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084516606
    126 rdf:type schema:CreativeWork
    127 https://doi.org/10.1016/j.jpedsurg.2014.03.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016066112
    128 rdf:type schema:CreativeWork
    129 https://doi.org/10.1016/s1470-2045(05)70291-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029499017
    130 rdf:type schema:CreativeWork
    131 https://doi.org/10.1055/s-0042-103158 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057376046
    132 rdf:type schema:CreativeWork
    133 https://doi.org/10.1056/nejmoa0911123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031306714
    134 rdf:type schema:CreativeWork
    135 https://doi.org/10.1056/nejmoa1001527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025117237
    136 rdf:type schema:CreativeWork
    137 https://doi.org/10.1148/rg.2016150099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079210596
    138 rdf:type schema:CreativeWork
    139 https://doi.org/10.1158/1078-0432.ccr-14-0817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000206075
    140 rdf:type schema:CreativeWork
    141 https://doi.org/10.1200/jco.1993.11.8.1466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082762676
    142 rdf:type schema:CreativeWork
    143 https://doi.org/10.1200/jco.1998.16.4.1256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083246609
    144 rdf:type schema:CreativeWork
    145 https://doi.org/10.1200/jco.2007.13.8925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016119423
    146 rdf:type schema:CreativeWork
    147 https://doi.org/10.1200/jco.2008.16.6876 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012354207
    148 rdf:type schema:CreativeWork
    149 https://doi.org/10.2967/jnumed.108.060467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042526688
    150 rdf:type schema:CreativeWork
    151 https://www.grid.ac/institutes/grid.418600.b schema:alternateName Cancer Institute
    152 schema:name Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India
    153 Department of Radiotherapy, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India
    154 Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India
    155 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...